[
    [
        {
            "time": "",
            "original_text": "动物疫苗概念大涨，普莱柯一度涨超9%",
            "features": {
                "keywords": [
                    "动物疫苗",
                    "概念",
                    "普莱柯",
                    "涨超9%"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "动物疫苗概念大涨，普莱柯一度涨超9%",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "【华兰生物】19Q3季报点评：四价流感放量推动Q3业绩超预期，单抗研发稳步推进",
            "features": {
                "keywords": [
                    "华兰生物",
                    "19Q3",
                    "四价流感",
                    "放量",
                    "业绩超预期",
                    "单抗研发"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【华兰生物】19Q3季报点评：四价流感放量推动Q3业绩超预期，单抗研发稳步推进",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "银河证券：主动公募19Q3重仓集中度达新高，抱团趋势延续",
            "features": {
                "keywords": [
                    "银河证券",
                    "主动公募",
                    "19Q3",
                    "重仓集中度",
                    "抱团趋势"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "基金"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "银河证券：主动公募19Q3重仓集中度达新高，抱团趋势延续",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "华兰生物2019三季报点评:四价流感放量推动Q3业绩超预期,单抗研发稳步推进",
            "features": {
                "keywords": [
                    "华兰生物",
                    "2019三季报",
                    "四价流感",
                    "放量",
                    "业绩超预期",
                    "单抗研发"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华兰生物2019三季报点评:四价流感放量推动Q3业绩超预期,单抗研发稳步推进",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华兰生物:四价流感贡献业绩弹性,19Q3业绩超市场预期",
            "features": {
                "keywords": [
                    "华兰生物",
                    "四价流感",
                    "业绩弹性",
                    "19Q3",
                    "业绩超市场预期"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华兰生物:四价流感贡献业绩弹性,19Q3业绩超市场预期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]